KOD — Kodiak Sciences Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1468748 ·
Last close
$96.80
Market Cap
$6.33B
52W High
$112.79
52W Low
$18.15
ADV30
1,042,205
Next earnings
2026-11-12
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -67,098,000 -66,223,000 209,413,000 88,678,000 196,841,000
Jun 2026 0 — -66,838,000 -65,643,000 256,811,000 125,903,000 195,715,000
Mar 2026 0 — -59,777,000 -58,158,000 306,006,000 169,530,000 193,905,000
Dec 2025 0 — -57,453,000 -56,736,000 351,533,000 209,862,000 194,150,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-158,505,000
Investing CF
$-1,397,000
Financing CF
$181,640,000
CapEx
$-1,397,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.19
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,682,506,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-241,999,000
Pretax Income TTM
$-241,994,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -234,388,000 -229,967,000 351,533,000 194,150,000 157,383,000 -136,008,000
Dec 2024 0 -186,849,000 -176,207,000 335,578,000 185,290,000 150,288,000 -117,319,000
Dec 2023 0 -277,321,000 -260,491,000 479,372,000 213,591,000 265,781,000 -154,183,000
Dec 2022 0 -341,379,000 -333,823,000 666,628,000 230,461,000 436,167,000 -206,459,000

TTM Snapshot

Revenues TTM
$4,570,000
NetIncome TTM
$-241,994,000
OpCashFlow TTM
—
Assets (Latest)
$256,811,000
Forward EPS
$-3.44

Max Pain — expiry 2026-12-18

max pain strike: $90.00 · spot: $97.81 · call oi: 5,051 · put oi: 2,622
Expected Move to 2026-12-18: ±$20.50 (20.96%) — implied range $77.31 – $118.31 · ATM straddle on $100.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IBRX ImmunityBio, Inc. $6.66B $6.26 —
IMVT Immunovant, Inc. $6.87B $33.21 —
CGON CG Oncology, Inc. $7.00B $78.94 —
SRRK Scholar Rock Holding Corp $5.50B $45.08 —
TWST Twist Bioscience Corp $7.43B $112.00 —

News headlines (Yahoo Finance, 1h cache)

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-12 21:00 · Yahoo
Kodiak Sciences to Present at Three Upcoming Investor Conferences
2026-11-11 23:43 · Yahoo
Kodiak Sciences (KOD) Stock Looks At A Premium On Its Huge 3 Year Run
2026-11-10 02:10 · Yahoo
Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
2026-10-08 19:12 · Yahoo
Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
2026-10-08 15:13 · Yahoo
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
2026-10-07 11:00 · Yahoo
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
2026-10-02 18:02 · Yahoo
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
2026-10-02 15:00 · Yahoo
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
2026-10-01 14:57 · Yahoo
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
2026-09-30 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.